← CVS HEALTH Corp

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $5.3b $6.6b ($594.0m) $6.6b $7.2b $7.9b $4.1b $8.3b $4.6b $1.8b
Net Income (Loss) Available to Common Stockholders, Basic $5.3b $6.6b ($596.0m) $6.6b $7.2b $7.9b $4.2b $8.3b $4.6b $1.8b
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $5.3b $6.6b ($597.0m) $6.6b $7.2b $7.9b $4.1b — — —
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $5.3b $6.6b ($596.0m) $6.6b $7.2b $7.9b $4.2b — — —
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($1.0m) ($8.0m) $0 $0 ($9.0m) $0 $0 — — —
Net Income (Loss) Attributable to Noncontrolling Interest $2.0m $1.0m ($2.0m) ($3.0m) $13.0m ($12.0m) $16.0m $24.0m ($28.0m) ($40.0m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $5.3b $6.6b ($596.0m) $6.6b $7.2b $7.9b $4.2b $8.4b $4.6b $1.7b
Amortization of Intangible Assets $795.0m $817.0m $1.0b $2.4b $2.3b $2.3b $1.8b $1.9b $2.0b $2.0b
Deferred Policy Acquisition Costs, Amortization Expense — — — — — — — $265.0m $299.0m $346.0m
Depreciation $1.7b $1.7b $1.7b $1.9b $2.1b $2.3b $2.4b $2.5b $2.6b $2.6b
Depreciation, Depletion and Amortization $2.5b $2.5b $2.7b $4.4b $4.4b $4.5b $4.2b $4.4b $4.6b $4.6b
Deferred Income Tax Expense (Benefit) $3.0m ($1.4b) $23.0m ($649.0m) ($564.0m) ($428.0m) ($2.1b) ($676.0m) ($572.0m) $102.0m
Deferred income taxes $18.0m ($1.3b) $87.0m ($654.0m) ($570.0m) ($428.0m) ($2.1b) ($676.0m) ($572.0m) $102.0m
Goodwill impairment $0 $181.0m $6.1b $0 $0 $431.0m $0 $0 $0 $5.7b
Goodwill, Impairment Loss — $181.0m $6.1b $0 $0 $431.0m $0 $0 $0 $5.7b
Impairment of Intangible Assets, Finite-lived — — $0 — — — — — — —
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) — — $0 $0 $0 $0 $0 $0 $0 $0
Payment, Tax Withholding, Share-based Payment Arrangement — $71.0m $97.0m $112.0m $88.0m $168.0m $370.0m $181.0m $185.0m $158.0m
Restructuring Costs and Asset Impairment Charges — — — — — — $0 $507.0m $1.2b $0
Restructuring charges (impairment of long-lived assets) — — — — — — $0 $152.0m $840.0m $0
Share-based Payment Arrangement, Expense $222.0m $234.0m $280.0m $453.0m $400.0m $484.0m $447.0m $588.0m $540.0m $535.0m
Share-based Payment Arrangement, Noncash Expense $222.0m $234.0m $280.0m $453.0m $400.0m $484.0m $447.0m $588.0m $540.0m $535.0m
Gain (Loss) on Disposition of Business — — — $205.0m $269.0m $0 $475.0m $0 $0 ($236.0m)
Gain (Loss) on Extinguishment of Debt ($643.0m) $0 $0 ($79.0m) ($1.4b) ($452.0m) $0 $0 $491.0m $0
Gain on early extinguishment of debt $643.0m $0 $0 $79.0m $1.4b $452.0m $0 $0 ($491.0m) $0
Income Tax Expense (Benefit) $3.3b $1.6b $2.0b $2.4b $2.6b $2.5b $1.5b $2.8b $1.6b $408.0m
Interest Expense Nonoperating — — — — — — — — $3.0b $3.1b
Other Nonoperating Income (Expense) — — $4.0m $124.0m $206.0m $182.0m $169.0m $88.0m $99.0m $112.0m
Changes in operating assets and liabilities:
Additional Financial Items
Accounts Receivable, Credit Loss Expense (Reversal) — — $256.0m $111.0m — — — — — —
Accounts payable and pharmacy claims and discounts payable $2.2b $1.7b $2.5b $3.5b $2.8b $2.9b $4.3b $3.6b $2.3b $3.9b
Accounts receivable, net ($243.0m) ($941.0m) ($1.1b) ($2.2b) ($1.5b) ($2.7b) ($3.0b) ($6.3b) ($1.3b) ($3.5b)
Accrued capital expenditures $2.2b $1.9b $2.0b $2.5b $2.4b $2.5b $2.7b $3.0b $2.8b $2.8b
Cash paid for inventory, prescriptions dispensed and health services rendered ($140.3b) ($146.5b) ($148.8b) ($149.7b) ($158.6b) ($165.8b) ($189.8b) ($208.8b) ($197.7b) ($216.5b)
Cash paid to other suppliers and employees ($15.6b) ($15.3b) ($17.2b) ($28.9b) ($29.8b) ($31.7b) ($32.7b) ($34.7b) ($38.8b) ($37.6b)
Cash receipts from customers $172.3b $176.6b $186.5b $248.4b $264.3b $284.2b $313.7b $345.5b $358.0b $389.1b
Commercial paper borrowings (repayments), net — — — — — $0 $0 $200.0m $1.9b ($2.1b)
Deconsolidation, Gain (Loss), Amount — — — — — — — — — $483.0m
Gain (Loss) Related to Litigation Settlement — — — — — — ($5.8b) $0 ($100.0m) —
Gain on deconsolidation of subsidiary — — — — — — — $0 $0 ($483.0m)
Goodwill $38.2b $38.5b $78.7b $79.7b $79.6b $79.1b $78.2b $91.3b $91.3b $85.5b
Health care costs payable and other insurance liabilities ($19.0m) $0 ($471.0m) $320.0m ($231.0m) $169.0m $1.2b $394.0m $2.8b $16.0m
Increase (Decrease) in Accounts Payable $2.2b $1.7b $2.5b $3.5b $2.8b $2.9b $4.3b $3.6b $2.3b $3.9b
Increase (Decrease) in Accounts Receivable $243.0m $941.0m $1.1b $2.2b $1.5b $2.7b $3.0b $6.3b $1.3b $3.5b
Increase (Decrease) in Inventories $742.0m $514.0m $1.2b $1.1b $973.0m ($735.0m) $1.4b ($1.2b) $102.0m $1.3b
Increase (Decrease) in Other Operating Assets $43.0m ($3.0m) — $614.0m ($364.0m) $3.0m $566.0m $510.0m $38.0m $2.6b
Increase (Decrease) in Other Operating Liabilities $2.0m $38.0m $165.0m $1.5b $2.7b $2.9b $6.5b $1.5b ($3.5b) $2.0b
Insurance benefits paid ($2.2b) ($2.8b) ($7.1b) ($52.2b) ($55.1b) ($63.6b) ($69.7b) ($84.1b) ($109.5b) ($121.2b)
Interest and investment income received $20.0m $21.0m $644.0m $955.0m $894.0m $743.0m $1.0b $1.6b $1.7b $2.0b
Inventories ($742.0m) ($514.0m) ($1.2b) ($1.1b) ($973.0m) $735.0m ($1.4b) $1.2b ($102.0m) ($1.3b)
Investment Income, Interest $20.0m $21.0m — — — — — — — —
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims — — — — — — — $86.0b $114.8b $125.3b
Loss on assets held for sale — — — — $0 $0 $2.5b $349.0m $0 $0
Loss on sale of subsidiary — $0 $86.0m $205.0m ($269.0m) $0 ($475.0m) $0 $0 $236.0m
Operating Expenses $18.5b $19.0b — $33.5b — — — — — —
Other ($5.0m) ($1.0m) $1.0m $0 ($27.0m) $155.0m ($79.0m) ($201.0m) $26.0m $0
Other assets ($43.0m) $3.0m ($3.0m) ($614.0m) $364.0m ($3.0m) ($566.0m) ($510.0m) ($38.0m) ($2.6b)
Other items $135.0m $53.0m $339.0m $264.0m $72.0m ($390.0m) $332.0m $416.0m ($502.0m) ($336.0m)
Other liabilities $2.0m $38.0m $165.0m $1.5b $2.7b $2.9b $6.5b $1.5b ($3.5b) $2.0b
Payments for taxes related to net share settlement of equity awards ($72.0m) ($71.0m) ($97.0m) ($112.0m) ($88.0m) ($168.0m) ($370.0m) ($181.0m) ($185.0m) ($158.0m)
Proceeds from Stock Options Exercised $224.0m $329.0m $242.0m $210.0m $264.0m $549.0m $551.0m $277.0m $361.0m $394.0m
Proceeds from exercise of stock options $224.0m $329.0m $242.0m $210.0m $264.0m $549.0m $551.0m $277.0m $361.0m $394.0m
Proceeds from issuance of short-term loan — — — — — $0 $0 $5.0b $0 $0
Realized Investment Gains (Losses) — — $3.0m $199.0m $52.0m $176.0m ($320.0m) ($497.0m) $117.0m ($44.0m)
Repayment of short-term loan — — — — — $0 $0 ($5.0b) $0 $0
Stock-based compensation $222.0m $234.0m $280.0m $453.0m $400.0m $484.0m $447.0m $588.0m $540.0m $535.0m
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement — ($187.0m) $0 $0 — — — — — —
Net Cash Provided by (Used in) Operating Activities $10.1b $8.0b $8.9b $12.8b $15.9b $18.3b $16.2b $13.4b $9.1b $10.6b
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $2.2b $1.9b $2.0b $2.5b $2.4b $2.5b $2.7b $3.0b $2.8b $2.8b
Payments to Acquire Businesses, Net of Cash Acquired $539.0m $1.3b $42.2b $444.0m $866.0m $146.0m $139.0m $16.6b $95.0m $436.0m
Payments to Acquire Investments — — $692.0m $7.5b $9.6b $10.0b $7.7b $9.0b $15.2b $15.0b
Purchases of investments ($80.0m) ($137.0m) ($692.0m) ($7.5b) ($9.6b) ($10.0b) ($7.7b) ($9.0b) ($15.2b) ($15.0b)
Proceeds from sales and maturities of investments $91.0m $61.0m $817.0m $7.0b $6.5b $7.2b $6.7b $7.7b $10.4b $12.4b
Payments for (Proceeds from) Other Investing Activities — — ($21.0m) ($42.0m) $0 ($122.0m) ($85.0m) ($68.0m) ($101.0m) ($26.0m)
Net Cash Provided by (Used in) Investing Activities ($2.5b) ($2.9b) ($43.3b) ($3.3b) ($5.5b) ($5.3b) ($5.0b) ($20.9b) ($7.6b) ($5.9b)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $3.5b $0 $44.3b $3.7b $10.0b $987.0m $0 $10.9b $7.9b $4.0b
Repayments of Long-term Debt $5.9b $0 $5.5b $8.3b $15.6b $10.3b $4.2b $3.2b $4.8b $3.6b
Payments for Repurchase of Common Stock $4.5b $4.4b $0 $0 $0 $0 $3.5b $2.0b $3.0b $0
Repurchase of common stock ($4.5b) ($4.4b) $0 $0 $0 $0 ($3.5b) ($2.0b) ($3.0b) $0
Proceeds from (Payments to) Noncontrolling Interests — — $0 — — — — — — —
Dividends paid $2k $2k $2k $3k $3k $3k $3k $3k $3k $3k
Payments of Dividends $2k $2k $2k $3k $3k $3k $3k $3k $3k $3k
Proceeds from (Payments for) Other Financing Activities ($5.0m) ($1.0m) $1.0m $0 ($27.0m) $155.0m ($79.0m) ($201.0m) $26.0m $0
Net Cash Provided by (Used in) Financing Activities ($6.7b) ($6.8b) $36.8b ($7.8b) ($8.2b) ($11.4b) ($10.5b) $2.7b ($1.1b) ($4.9b)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $912.0m ($1.6b) ($4.0m) $0 $0 $1.6b $614.0m ($4.8b) $359.0m ($172.0m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $912.0m ($1.6b) $2.4b $1.7b $2.2b $1.6b $614.0m ($4.8b) $359.0m ($172.0m)
Net increase (decrease) in cash, cash equivalents and restricted cash $912.0m ($1.6b) $2.4b $1.7b $2.2b $1.6b $614.0m ($4.8b) $359.0m ($172.0m)
Acquisitions (net of cash and restricted cash acquired) ($539.0m) ($1.3b) ($42.2b) ($444.0m) ($866.0m) ($146.0m) ($139.0m) ($16.6b) ($95.0m) ($436.0m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $912.0m ($1.6b) $4.3b $6.0b $8.1b $12.7b $13.3b $8.5b $8.9b $8.7b
Cash, cash equivalents and restricted cash at the beginning of the period $3.5b $1.9b $4.3b $6.0b $8.1b $12.7b $13.3b $8.5b $8.9b $8.7b
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities ($1.1b) $1.1b $2.8b $3.0b $2.9b $2.5b $2.2b $2.4b $2.9b $3.0b
Income Taxes Paid, Net ($3.1b) $2.9b $2.4b $2.7b $2.9b $3.2b $4.1b $3.5b $1.7b $2.2b

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.